There is recently published indirect evidence suggesting that SGLT-2 inhibitors and GLP-1RA are effective in frail compared to non-frail older persons with diabetes, and the benefits increase with the increase in severity of frailty [113]. This evidence concerns the gene SLC5A2 and diabetes mellitus.